Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongxia Wei

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
The Lancet Regional Health. Western Pacific|August 2, 2024
Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF <i>versus</i> elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trialFujie Zhang, Hao Wu, Weiping Cai, et al.
Current Pharmaceutical Design|July 30, 2013
Epigenetic interventions increase the radiation sensitivity of cancer cellsJuan Ren, Yongli Chu, Hongbing Ma, et al.
Frontiers in Public Health|July 29, 2020
Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia ProgressionZhiliang Hu, Yanling Lv, Chuanjun Xu, et al.
BMC Medicine|October 1, 2025
Immediate and delayed switches to tenofovir DF-containing, ainuovirine-based antiretroviral regimen: the SPRINT extensional studyFujie Zhang, Weiping Cai, Hao Wu, et al.
Current Pharmaceutical Design|July 30, 2013
Relations between GPR4 expression, microvascular density (MVD) and clinical pathological characteristics of patients with epithelial ovarian carcinoma (EOC)Juan Ren, Wen Jin, Yan-E Gao, et al.
Emerging Microbes & Infections|April 9, 2020
Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trialJun Chen, Rong Chen, Yinzhong Shen, et al.
Current Pharmaceutical Design|July 30, 2013
HDAC as a therapeutic target for treatment of endometrial cancersJuan Ren, Jia Zhang, Hui Cai, et al.
Oncology Reports|February 4, 2015
GPER in CAFs regulates hypoxia-driven breast cancer invasion in a CTGF-dependent mannerJuan Ren, Hui Guo, Huili Wu, et al.
Molecular Medicine Reports|June 10, 2016
Human GPR4 and the Notch signaling pathway in endothelial cell tube formationJuan Ren, Yuelang Zhang, Hui Cai, et al.
International Journal of Clinical and Experimental Medicine|April 23, 2014
RNAi targeting GPR4 influences HMEC-1 gene expression by microarray analysisJuan Ren, Yuelang Zhang, Hui Cai, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
The Lancet Regional Health. Western Pacific|August 2, 2024
Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF <i>versus</i> elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trialFujie Zhang, Hao Wu, Weiping Cai, et al.
Current Pharmaceutical Design|July 30, 2013
Epigenetic interventions increase the radiation sensitivity of cancer cellsJuan Ren, Yongli Chu, Hongbing Ma, et al.
Frontiers in Public Health|July 29, 2020
Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia ProgressionZhiliang Hu, Yanling Lv, Chuanjun Xu, et al.
BMC Medicine|October 1, 2025
Immediate and delayed switches to tenofovir DF-containing, ainuovirine-based antiretroviral regimen: the SPRINT extensional studyFujie Zhang, Weiping Cai, Hao Wu, et al.
Current Pharmaceutical Design|July 30, 2013
Relations between GPR4 expression, microvascular density (MVD) and clinical pathological characteristics of patients with epithelial ovarian carcinoma (EOC)Juan Ren, Wen Jin, Yan-E Gao, et al.
Emerging Microbes & Infections|April 9, 2020
Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trialJun Chen, Rong Chen, Yinzhong Shen, et al.
Current Pharmaceutical Design|July 30, 2013
HDAC as a therapeutic target for treatment of endometrial cancersJuan Ren, Jia Zhang, Hui Cai, et al.
Oncology Reports|February 4, 2015
GPER in CAFs regulates hypoxia-driven breast cancer invasion in a CTGF-dependent mannerJuan Ren, Hui Guo, Huili Wu, et al.
Molecular Medicine Reports|June 10, 2016
Human GPR4 and the Notch signaling pathway in endothelial cell tube formationJuan Ren, Yuelang Zhang, Hui Cai, et al.
International Journal of Clinical and Experimental Medicine|April 23, 2014
RNAi targeting GPR4 influences HMEC-1 gene expression by microarray analysisJuan Ren, Yuelang Zhang, Hui Cai, et al.
Pageof 11